In the present study, the effectiveness of the simultaneous administration of muscarinic ligands (VU0357017, VU0152100, and VU0238429) with a biased agonist of 5-HT1A receptors (F15599) (the chemical structures of the compounds are presented on Figure 1) at reversing schizophrenia-related cognitive disturbances was examined in behavioral tests assessing memory processes (NOR test and Y-maze). Here, HTR1A is linked to schizophrenia.